Clinical trial
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally…
NCT00258349 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00258349 |
|---|---|
| Title | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer |
| Official title | A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug |
| Interventions | vorinostat, trastuzumab |
| Enrollment | 16 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Nov 24, 2005 |
| Last update posted | Jun 2, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: